High levels of uPA and PAI-1 predict a good response to anthracyclines.
Pritchard
Kathleen I
KI
Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada. kathy.pritchard@sunnybrook.ca
D018943:Anthracyclines / Q000494:pharmacology* / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D011237:Predictive Value of Tests; D012107:Research Design; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D017395:Plasminogen Activator Inhibitor 1; D014568:Urokinase-Type Plasminogen Activator